Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Monday

Aquestive Therapeutics (NASDAQ:AQST) is anticipated to issue its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $12.9440 million for the quarter. Aquestive Therapeutics has set its FY 2025 guidance at EPS.Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:00 AM ET.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. The business had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $11.32 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aquestive Therapeutics Stock Down 2.4%

AQST stock opened at $6.84 on Monday. The business has a 50 day moving average price of $5.37 and a 200 day moving average price of $4.01. The stock has a market cap of $682.08 million, a price-to-earnings ratio of -9.77 and a beta of 1.77. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $7.55.

Insider Buying and Selling

In other news, insider Peter E. Boyd sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $5.30, for a total value of $79,500.00. Following the transaction, the insider owned 288,323 shares of the company’s stock, valued at approximately $1,528,111.90. The trade was a 4.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Cassie Jung sold 67,575 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $7.01, for a total value of $473,700.75. Following the completion of the transaction, the chief operating officer directly owned 240,771 shares in the company, valued at approximately $1,687,804.71. The trade was a 21.92% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 276,770 shares of company stock worth $1,692,203. 7.85% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets increased its holdings in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after purchasing an additional 4,134 shares during the period. Modern Wealth Management LLC purchased a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $33,000. The Manufacturers Life Insurance Company boosted its stake in shares of Aquestive Therapeutics by 16.6% in the second quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company’s stock valued at $106,000 after buying an additional 4,557 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Aquestive Therapeutics by 6.0% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock valued at $156,000 after buying an additional 2,649 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $217,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Analyst Ratings Changes

AQST has been the subject of several recent analyst reports. Lifesci Capital upgraded Aquestive Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 3rd. Citigroup reaffirmed an “outperform” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Friday. JMP Securities lifted their price target on Aquestive Therapeutics from $9.00 to $12.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 9th. Finally, Zacks Research raised Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.33.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.